AKT1 and breast carcinoma: miR-142-3p, which suppresses expression of the oncogene HMGA1 and targets the AKT/ERK/STAT3 pathway, is supposed to be a new miRNA for breast cancer therapy that restores this suppressive miRNA in tumor breast cells using a targeted nanoparticle delivery system [176,188].